Literature DB >> 21516199

Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.

Maria L Ekstrand1, Anita Shet, Sara Chandy, Girija Singh, Ranjani Shamsundar, Vidya Madhavan, Shanmugam Saravanan, Elsa Heylen, Nagalingeswaran Kumarasamy.   

Abstract

This study was conducted to examine the relationship between adherence, viral load (VL) and resistance among outpatients receiving highly active antiretroviral therapy (HAART) in Bangalore, India. In total, 552 outpatients were recruited and VL testing was conducted for all study participants. HIV-1 genotypic resistance testing was performed for 92 participants with a VL ≥ 1000 copies/ml. Interpretation of resistance mutations was performed according to the Stanford database. Past-month adherence and treatment interruptions for >48 h were assessed via self-report. At baseline, 34 participants (6%) reported <95% past-month adherence and 110 (20%) reported a history of >48 h treatment interruptions. Combining the two adherence measures, 22% of participants were classified as 'suboptimally adherent'. In total, 24% of study participants (n = 132) had a detectable VL. Among the 92 samples sent for resistance testing, 68% had at least one nucleoside reverse transcriptase inhibitor (NRTI) mutation, with M184V being the most common (62%) and with 48% having thymidine analogue mutations. Moreover, 72% had at least one non-nucleoside reverse transcriptase inhibitor (NNRTI) mutation and 23% had three or more NNRTI mutations. Both adherence measures were significantly associated with VL (P < 0.001). Suboptimal adherence was significantly associated with resistance mutations (P < 0.02). The findings illustrate for the first time the strong association between suboptimal adherence, treatment failure and drug resistance to first-line HAART in India. The predictive value of standard adherence measures was improved by including treatment interruption data. The observed mutations can jeopardise future treatment options, especially in light of limited access to second-line treatments. To develop effective adherence interventions, research is needed to examine culturally-specific reasons for treatment interruptions.

Entities:  

Year:  2011        PMID: 21516199      PMCID: PMC3079268          DOI: 10.1016/j.inhe.2010.11.003

Source DB:  PubMed          Journal:  Int Health        ISSN: 1876-3405            Impact factor:   2.473


  54 in total

1.  HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy.

Authors:  Rami Kantor; Lynn S Zijenah; Robert W Shafer; Solomon Mutetwa; Elizabeth Johnston; Robert Lloyd; Andrea von Lieven; Dennis Israelski; David A Katzenstein
Journal:  AIDS Res Hum Retroviruses       Date:  2002-12-10       Impact factor: 2.205

2.  Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India, and detection of rare resistance mutations.

Authors:  Alaka Deshpande; Patricia Recordon-Pinson; Ranjana Deshmukh; Muriel Faure; Valérie Jauvin; Isabelle Garrigue; Marie-Edith Lafon; Hervé J Fleury
Journal:  AIDS Res Hum Retroviruses       Date:  2004-09       Impact factor: 2.205

3.  Running with scissors: using antiretroviral therapy without monitoring viral load.

Authors:  Davey M Smith; Robert T Schooley
Journal:  Clin Infect Dis       Date:  2008-05-15       Impact factor: 9.079

4.  Naturally occurring polymorphisms and primary drug resistance profile among antiretroviral-naive individuals in Bangalore, India.

Authors:  Ujjwal Neogi; B S Prarthana; Soham Gupta; George D'souza; Ayesha De Costa; Vijesh Sreedhar Kuttiatt; Karthika Arumugam; Anita Shet
Journal:  AIDS Res Hum Retroviruses       Date:  2010-09-13       Impact factor: 2.205

5.  Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale.

Authors:  Thomas P Giordano; David Guzman; Richard Clark; Edwin D Charlebois; David R Bangsberg
Journal:  HIV Clin Trials       Date:  2004 Mar-Apr

6.  Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method.

Authors:  S Saravanan; M Vidya; P Balakrishnan; P Balakrishanan; N Kumarasamy; Sunil S Solomon; S Solomon; Rami Kantor; David Katzenstein; Bharat Ramratnam; Kenneth H Mayer
Journal:  J Virol Methods       Date:  2009-04-02       Impact factor: 2.014

7.  Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.

Authors:  Jessica H Oyugi; Jayne Byakika-Tusiime; Kathleen Ragland; Oliver Laeyendecker; Roy Mugerwa; Cissy Kityo; Peter Mugyenyi; Thomas C Quinn; David R Bangsberg
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

8.  Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.

Authors:  Jean-Jacques Parienti; Véronique Massari; Diane Descamps; Astrid Vabret; Elisabeth Bouvet; Bernard Larouzé; Renaud Verdon
Journal:  Clin Infect Dis       Date:  2004-04-14       Impact factor: 9.079

9.  Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.

Authors:  B T Røge; T S Barfod; O Kirk; T L Katzenstein; N Obel; H Nielsen; C Pedersen; L R Mathiesen; J D Lundgren; J Gerstoft
Journal:  HIV Med       Date:  2004-09       Impact factor: 3.180

10.  Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India.

Authors:  Madhavan Vidya; Shanmugam Saravanan; Shanmugasundaram Uma; Nagalingeswaran Kumarasamy; Solomon S Sunil; Rami Kantor; David Katzenstein; Bharat Ramratnam; Kenneth H Mayer; Solomon Suniti; Pachamuthu Balakrishnan
Journal:  Antivir Ther       Date:  2009
View more
  42 in total

1.  Stigma is associated with delays in seeking care among HIV-infected people in India.

Authors:  Wayne T Steward; Shalini Bharat; Jayashree Ramakrishna; Elsa Heylen; Maria L Ekstrand
Journal:  J Int Assoc Provid AIDS Care       Date:  2012-01-26

Review 2.  Systematic review of HIV drug resistance in Southeast Asia.

Authors:  Andrew B Trotter; Steven Y Hong; Padmini Srikantiah; Iyanthi Abeyewickreme; Silvia Bertagnolio; Michael R Jordan
Journal:  AIDS Rev       Date:  2013 Jul-Sep       Impact factor: 2.500

3.  Pharmacy and self-report adherence measures to predict virological outcomes for patients on free antiretroviral therapy in Tamil Nadu, India.

Authors:  James H McMahon; Anand Manoharan; Christine A Wanke; Shoba Mammen; Hepsibah Jose; Thabeetha Malini; Tony Kadavanu; Michael R Jordan; Julian H Elliott; Sharon R Lewin; Dilip Mathai
Journal:  AIDS Behav       Date:  2013-07

4.  Sustained Effect of a Community-based Behavioral and Nutrition Intervention on HIV-related Outcomes Among Women Living With HIV in Rural India: A Quasi-experimental Trial.

Authors:  Adeline M Nyamathi; Sanghyuk S Shin; Sanjeev Sinha; Catherine L Carpenter; Dana Rose Garfin; Padma Ramakrishnan; Kartik Yadav; Maria L Ekstrand
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-01       Impact factor: 3.731

5.  ASHA-Life Intervention Perspectives Voiced by Rural Indian Women Living With AIDS.

Authors:  Adeline Nyamathi; Maria Ekstrand; Neha Srivastava; Catherine L Carpenter; Benissa E Salem; Shawana Al-Harrasi; Padma Ramakrishnan; Sanjeev Sinha
Journal:  Health Care Women Int       Date:  2015-07-06

6.  A Behavioral Adherence Intervention Improves Rates of Viral Suppression Among Adherence-Challenged People Living with HIV in South India.

Authors:  Maria L Ekstrand; Elsa Heylen; Matilda Pereira; Jacob D'Souza; Shoba Nair; Amanda Mazur; Ranjani Shamsundar; B N Ravi Kumar; Sara Chandy
Journal:  AIDS Behav       Date:  2020-07

7.  Reasons for and correlates of antiretroviral treatment interruptions in a cohort of patients from public and private clinics in southern India.

Authors:  Snigdha Vallabhaneni; Sara Chandy; Elsa Heylen; Maria Ekstrand
Journal:  AIDS Care       Date:  2011-11-22

8.  Antiretroviral therapy adherence measurement in non-clinical settings in South India.

Authors:  Nora J Kleinman; Lisa E Manhart; Rani Mohanraj; Shuba Kumar; Lakshmanan Jeyaseelan; Deepa Rao; Jane M Simoni
Journal:  AIDS Care       Date:  2014-08-14

9.  Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

Authors:  R M Savic; A Barrail-Tran; X Duval; G Nembot; X Panhard; D Descamps; C Verstuyft; B Vrijens; A-M Taburet; C Goujard; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2012-10-03       Impact factor: 6.875

10.  Randomized controlled trial of a community-based intervention on HIV and nutritional outcomes at 6 months among women living with HIV/AIDS in rural India.

Authors:  Adeline M Nyamathi; Catherine L Carpenter; Maria L Ekstrand; Kartik Yadav; Dana Rose Garfin; Lisa C Muniz; Mariko Kelley; Sanjeev Sinha
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.